Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
Open Access
- 10 July 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1208740
Abstract
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.Keywords
This publication has 68 references indexed in Scilit:
- Targeting renal cell carcinoma with a HIF-2 antagonistNature, 2016
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsNature, 2016
- Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney CancerCancer Cell, 2016
- GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputersSoftwareX, 2015
- New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of DiseaseClinical Cancer Research, 2015
- iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA ApproachJournal of Chemical Information and Modeling, 2014
- Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor ActivityJournal of Medicinal Chemistry, 2014
- New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in BioassaysJournal of Medicinal Chemistry, 2010
- Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative StressCancer Research, 2009
- Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer CellsClinical Cancer Research, 2009